The Importance of Antibiotics in Oncology Supportive Care
|
|
- Alfred McKinney
- 6 years ago
- Views:
Transcription
1 The Importance of Antibiotics in Oncology Supportive Care The emergence of drug resistant bacterial pathogens is a significant problem, particularly in high risk patient populations. The development of novel antibiotic agents, the judicious use of antimicrobial agents through antibiotic stewardship, and adherence to infection control procedures will limit the emergence and spread of resistant organisms, improve patient outcomes, and preserve our therapeutic armamentarium for more prolonged usage. 1 Key facts about infections in oncology patients Infections are the leading cause of morbidity and a major cause for mortality in cancer patients. 2,3 Chemotherapy and radiation therapy weaken the immune system and leave patients at increased risk of infection. 4 Chemotherapy induced fever occurs in about 50% of patients with solid tumors and in greater than 80% of patients with blood cancers and clinically documented infections occur in about 20 30% of these patients. 5 About 50% of all microbiologically documented infections in Leukemia patients are caused by Gram positive organisms, chiefly coagulase negative Staphylococci, Staphylococcus aureus and Enterococcus species. All these pathogens show resistance patters that are geographically variable, ranging from > 90% methicillin resistance in coagulase negative Staphylococci to 50% S.aureus methicillin resistance to 25% Vancomycin resistant Enterococci. 6 Antecedent chemotherapy has been identified as a risk factor for development of bloodstream infections. The overall fatality rates reported for cancer patients with bloodstream infections range from 13% (S.aureus infections) up to 48% (P.aeruginosa infections). 7 Key facts about infections in pediatric oncology patients Infections are second only to malignancies as cause of death in children with cancer. At least half of children with hematologic malignancies will contract an infection at some point during the course of their therapy. 8 1
2 Children undergoing chemotherapy to treat cancer often suffer from complications infections are chief among them. 9 Infections not only contribute to mortality but also prolong hospital stays, make chemotherapy more complicated and affect quality of life. 10 One large study compared the rates of Methicillin resistant Staphylococcus aureus (MRSA) colonization in pediatric oncology patients between 2000/2001 and 2006/2007. The rates of colonization increased from 0.6% to 2.9%. MRSA colonization was associated with infection and prevalence of infection increased from 0.99% to 3.7%. Recurrent MRSA infections were seen in 22% of patients. 11 Prophylactic use of antibiotics can improve outcomes and reduce the cost of care for children suffering from various forms of cancer. 12,13 However, the widespread use of prophylactic antibiotic therapy has also induced development of resistance which is quickly becoming a major concern in supportive care. 14 References 1. Rolston KV. Clin Lymphoma Myeloma. 2009;9 Suppl 3:S The use of new and better antibiotics for bacterial infections in patients with leukemia. 2.Pongas G, Hamilos G, Rolston KV, Kontoyiannis DP. Support Care Cancer Dec 30. Formal adult infectious disease specialist consultations in the outpatient setting at a comprehensive cancer center ( ): Diverse and impactful. 3. Maschmeyer G, Haas A. Int J Antimicrob Agents Mar;31(3): Epub 2007 Aug 20.The epidemiology and treatment of infections in cancer patients 4. Rapoport BL. Semin Oncol Jun;38(3): Management of the cancer patient with infection and neutropenia. 5. Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, Raad II, Rolston KV, Young JA, Wingard JR, Infectious Diseases Society of America. Clin Infect Dis Feb 15;52(4):e Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. 6. Rolston KV. Clin Lymphoma Myeloma. 2009;9 Suppl 3:S The use of new and better antibiotics for bacterial infections in patients with leukemia. 7. Wisplinghoff H, Seifert H, Wenzel RP, Edmond MB Clin Infect Dis May 1;36(9): Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. 8. Bailey LC, Reilly AF, Rheingold SR. 2
3 Semin Hematol Jul;46(3): Infections in pediatric patients with hematologic malignancies. 9. Castagnola E, Caviglia I, Haupt R. Pediatr Rep Feb 24;3(1):e7. Guidelines for the management of bacterial and fungal infections during chemotherapy for pediatric acute leukemia or solid tumors: what is available in 2010? 10. Sung L, Lange BJ, Gerbing RB, Alonzo TA, Feusner J. Blood Nov 15;110(10): Epub 2007 Jul 27. Microbiologically documented infections and infection related mortality in children with acute myeloid leukemia. 11. Srinivasan A, Seifried SE, Zhu L, Srivastava DK, Perkins R, Shenep JL, Bankowski MJ, Hayden RT. Pediatr Blood Cancer Dec 15;55(7): doi: /pbc Epub 2010 Sep 9. Increasing prevalence of nasal and rectal colonization with methicillin resistant Staphylococcus aureus in children with cancer. 12. Kurt B, Flynn P, Shenep JL, Pounds S, Lensing S, Ribeiro RC, Pui CH, Razzouk BI, Rubnitz JE. Cancer Jul 15;113(2): Prophylactic antibiotics reduce morbidity due to septicemia during intensive treatment for pediatric acute myeloid leukemia. 13. Castagnola E, Boni L, Giacchino M, Cesaro S, De Sio L, Garaventa A, Zanazzo G, Biddau P, Rossi MR, Schettini F, Bruzzi P, Viscoli C; Infectious Diseases Study Group of the Italian Association of Pediatric Hematology and Oncology.Pediatr Infect Dis J Apr;22(4): A multicenter, randomized, double blind placebo controlled trial of amoxicillin/clavulanate for the prophylaxis of fever and infection in neutropenic children with cancer. 14. Castagnola E, Caviglia I, Haupt R. Pediatr Rep Feb 24;3(1):e7. Guidelines for the management of bacterial and fungal infections during chemotherapy for pediatric acute leukemia or solid tumors: what is available in 2010? 3
4 October 17, 2011 Margaret A. Hamburg, MD Commissioner U.S. Food and Drug Administration New Hampshire Ave., Bldg. 1, Rm Silver Spring, MD Dear Commissioner Hamburg: I write on behalf of the Infectious Diseases Society of America (IDSA) to further our ongoing discussion regarding regulatory challenges in the antibacterial and influenza antiviral drug development and approval pathways. You are well aware of the imminent public health crisis with the potential to affect our nation s security resulting from the simultaneous increase in antimicrobial drug resistance and the decrease in the development and rate of approval of new drugs. IDSA appreciates the Food and Drug Administration s (FDA) recent efforts in producing new antibacterial drug clinical trial guidelines. However, we are concerned that these guidelines still do not create feasible pathways for conducting antibacterial drug trials. In addition, pharmaceutical companies are continuing to eliminate or downsize their antibacterial research and development (R&D) portfolios. The current situation is untenable, and the remaining antibacterial R&D programs hang in a fragile balance. Similar challenges arise from FDA s current approach to clinical trials design for influenza antivirals, particularly parenteral antivirals for hospitalized patients who are too sick to be treated with placebo. We understand the difficulties that FDA faces in weighing the risks versus benefits in this area where the regulatory science is deficient. IDSA is supportive of FDA and sensitive to the agency s constraints, but we remain deeply concerned. We jointly seek the same outcome: new, safe and effective anti-infective drugs. Unfortunately, at this time, the micro-organisms are evolving faster than we are. For this reason, IDSA asks that you engage with the Institute of Medicine (IOM) to discuss options for developing a process to review the operational feasibility of FDA s current approaches to the design of antibacterial drug and influenza antiviral drug clinical trials. The IOM could: assess the limitations and strengths of FDA s current statistical approaches; provide new perspectives on approaches to balancing public health risk vs. benefit of decisions that must be made, even in the face of incomplete or imperfect data, and applied to the evaluation of the safety and efficacy of new anti-infective drugs; and make recommendations leading to more rapid improvements in regulatory science.
5 PAGE TWO IDSA Letter to Commissioner Hamburg on IOM Engagement Reaching out to IOM for its expertise at this time would be consistent with the ideals set out in FDA s recently released blueprint for Driving Biomedical Innovation: Initiatives to Improve Products for Patients. In that report, FDA noted: During the HIV epidemic in the early 1990s, experts from many fields came together to rapidly work through the science underlying the disease and devise programs for AIDS drug development. The result was a relatively efficient development process and availability of effective anti-hiv drugs. We need exactly that kind of initiative now in other areas of anti-infective drug development. IDSA leaders appreciate that, despite less than optimal human and financial resources, FDA is aggressively modernizing and clarifying anti-infective guidance documents. However, as IDSA leaders have noted in meetings with you and other FDA officials and in our formal comments, significant feasibility concerns persist with proposed guidances for Community-Acquired Bacterial Pneumonia (CABP), Hospital-Acquired Bacterial Pneumonia (HABP)/Ventilator- Associated Bacterial Pneumonia (VABP) and Acute Bacterial Skin and Skin Structure Infections (ABSSSI). IDSA also remains concerned about the need for feasible guidances in areas relevant to resistant Gram-negative bacterial infections, such as non-inferiority trials of complicated urinary tract infections (cuti), complicated intra-abdominal infections (ciai), organism-specific trials, and superiority trials. IDSA recently provided a similar assessment of FDA s guidance for developing influenza antivirals for treatment and/or prophylaxis in our comments submitted to the public docket on October 12. FDA s guidances, in some instances, appear to deviate substantively from standard clinical care and thereby may impede, rather than facilitate, anti-infective drug development. The realities of patient care may not allow compliance with regulatory guidance. Our greatest concern is the statistical approaches the agency is employing. It seems that many of the troublesome areas in the draft guidances result from, or are strongly influenced by, the desire for unqualified clinical data, like mortality, that is easily analyzed statistically. FDA s current approaches particularly impact study designs where the infection/disease is acute, life-threatening, and for which a placebo group has not been and cannot now be included. The clinical reality in these patients is that successful treatment is measured by reduction of fever, return of appetite, and normalization of biomarkers. We believe that statistical analysis should include such clinically relevant endpoints as well as microbiologic endpoints addressing the elimination of the infectious pathogen. In our earlier comments on the FDA draft HABP/VABP guidance, IDSA communicated two key points designed to improve the feasibility of HABP/VABP clinical trials: i.e., allowance for a brief period of antibiotic therapy prior to clinical enrollment; and the use of biomarkers as an adjunct and/or alternative to the collection of traditional respiratory culture specimens. Clinically, it is not possible to withhold the first dose of empiric therapy in HABP/VABP patients. These infections are caused by virulent highly antibiotic-resistant bacteria, occur in very debilitated hosts, and are treated with short half-life drugs, often in the setting of a foreign body (endotracheal tube). There is little chance that a single dose of a short-acting antibiotic is going to alter the clinical course of such infections. With regard to the proposed guidance for ABSSSI, the refusal to allow a single dose of a non-study antibiotic will make enrollment very
6 PAGE THREE IDSA Letter to Commissioner Hamburg on IOM Engagement challenging. These same issues complicate trial designs for other areas mentioned above, including CABP, UTI, ciai, etc. It is our understanding that many industry representatives also perceive FDA s proposed ABSSSI, CABP, and HAPB/VABP guidances to be infeasible to follow. In IDSA s recent comments on FDA s influenza antivirals guidance, we communicated that the guidance does not provide a realistic trial design for hospitalized patients, as the currently proposed designs would require unrealistically large numbers of patients and likely generate an outcome of non-superiority compared to available single agent neuraminidase inhibitor therapy. Instead we argued that an active-controlled, non-inferiority trial would not only be valid in hospitalized patients, but also would serve to promote more rapid antiviral drug development in the United States. Moreover, aspects of FDA s anti-infective guidances raise ethical concerns. The leading reason that companies voice for the dramatic decrease in new anti-infective R&D is the lack of clear and feasible instructions from FDA. Despite numerous joint workshops held by FDA and IDSA and the work of multiple FDA advisory committees, the perception of impossible regulatory hurdles persists. During a recent meeting hosted by IDSA, the Pew Health Group and the Pharmaceutical Research and Manufacturers Association (PhRMA), representatives from the few companies that remain in antibacterial drug development reported that FDA s current course is leading them to focus their future efforts on European, Asian, and Latin America markets and not on the United States. As physicians who treat patients in the U.S., we believe it is extremely important that antibacterial trials be designed in a fashion that permits them to be conducted in this country to ensure their results are generalizable to U.S. patients. We believe that the IOM could help break the logjam with an unbiased review, rooted in scientific expertise, and accelerate your goal of improving regulatory science. IOM recommendations could help advance a process in desperate need of momentum to the benefit of U.S. public health and national security. We hope you will seriously consider our request. We look forward to continuing to work with you and FDA staff to achieve a realistic and viable regulatory pathway that will re-invigorate antibacterial and influenza antiviral drug discovery and development. Please contact Robert J. Guidos, JD, IDSA s vice president for public policy and government relations, should you have any questions or comments, at rguidos@idsociety.org or Sincerely, James M. Hughes, MD, FIDSA President
Shannon Carty, PGY-2 ICCR IRB Project Proposal April 9, 2008
Shannon Carty, PGY-2 ICCR IRB Project Proposal April 9, 2008 Study Title: Observational Study to Determine the Effect of an Emergency Department Adult Oncology Stat Antibiotic Protocol on Clinical Outcomes
More informationRegulatory Standards and Guidances DAIP/OAP/CDER/FDA
Regulatory Standards and Guidances DAIP/OAP/CDER/FDA Joseph Toerner, MD MPH Associate Director for Clinical Affairs, OAP/CDER/ FDA CTTI Statistical Issues Think Tank II 19 November 2014 Statutory Standards
More informationOn behalf of the Infectious Diseases Society of America (IDSA), I am pleased to provide
Transmitted by Jonathan Nurse, Director of Government Relations, IDSA The Infectious Diseases Society of America s (IDSA) Fiscal Year 2015 Funding Statement Submitted to the House Appropriations Subcommittee
More informationClinical profile of high-risk febrile neutropenia in a tertiary care hospital
Clinical profile of high-risk febrile neutropenia in a tertiary care hospital Mohan V Bhojaraja 1, Sushma T Kanakalakshmi 2, Mukhyaprana M Prabhu 1, Joseph Thomas 3 1. Department of Medicine, Kasturba
More informationTreatment of febrile neutropenia in patients with neoplasia
Treatment of febrile neutropenia in patients with neoplasia George Samonis MD, PhD Medical Oncologist Infectious Diseases Specialist Professor of Medicine The University of Crete, Heraklion,, Crete, Greece
More informationNonallergic Rhinitis: Developing Drug Products for Treatment Guidance for Industry
Nonallergic Rhinitis: Developing Drug Products for Treatment Guidance for Industry DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding
More informationJuly 7, Dockets Management Branch (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm Rockville, MD 20852
July 7, 2012 Dockets Management Branch (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852 Re: Docket No. FDA 2012-N-0408: Risk Evaluation and Mitigation Strategy Assessments:
More informationAntimicrobial resistance Fact sheet N 194 Updated April 2014
Antimicrobial resistance Fact sheet N 194 Updated April 2014 Key facts Antimicrobial resistance (AMR) threatens the effective prevention and treatment of an ever-increasing range of infections caused by
More informationDAYTON CHILDREN S HOSPITAL CLINICAL PRACTICE GUIDELINES
DAYTON CHILDREN S HOSPITAL CLINICAL PRACTICE GUIDELINES DISCLAIMER: This Clinical Practice Guideline (CPG) generally describes a recommended course of treatment for patients with the identified health
More informationOn behalf of the Infectious Diseases Society of America (IDSA), I offer testimony in
Testimony of the Infectious Diseases Society of America (IDSA) on the Fiscal Year 2018 Department of Health and Human Services Budget Prepared for the U.S. House of Representatives Subcommittee on Labor-HHS-Education
More informationConsideration of some other specific indications: Bacteremia
European Medicines Agency Workshop on Antibacterials, London 7-8 February 2011 Consideration of some other specific indications: Bacteremia Harald Seifert Institut für Medizinische Mikrobiologie, Immunologie
More informationTrust Guideline for the Use of Parenteral Vancomycin and Teicoplanin in Adults
A clinical guideline recommended for use: In: By: For: Division responsible for document: Key words: Names of document authors: Job titles of document authors: Name of document author s Line Manager: Job
More informationBefore and during influenza pandemics
before and during influenza pandemics Klaus Stöhr Department for Communicable Diseases Surveillance and Response Before and during influenza pandemics Before pandemics: interpandemic period New human influenza
More informationFungi GUIDE TO INFECTION CONTROL IN THE HOSPITAL CHAPTER NUMBER 53: Author Moi Lin Ling, MBBS, FRCPA, CPHQ, MBA
GUIDE TO INFECTION CONTROL IN THE HOSPITAL CHAPTER NUMBER 53: Fungi Author Moi Lin Ling, MBBS, FRCPA, CPHQ, MBA Chapter Editor Ziad A. Memish, MD, FRCPC, FACP Cover heading - Topic Outline Topic outline
More informationDOWNLOAD OR READ : URINARY TRACT INFECTIONS IN CHILDREN PDF EBOOK EPUB MOBI
DOWNLOAD OR READ : URINARY TRACT INFECTIONS IN CHILDREN PDF EBOOK EPUB MOBI Page 1 Page 2 urinary tract infections in children urinary tract infections in pdf urinary tract infections in children MID 11
More informationWHICH ANTIFUNGAL AGENT IS THE CHOICE FOR SUSPECTED FUNGAL INFECTIONS?
WHICH ANTIFUNGAL AGENT IS THE CHOICE FOR SUSPECTED FUNGAL INFECTIONS? Assoc. Prof. Dr. Serkan SENER Acibadem University Medical School Department of Emergency Medicine, Istanbul Acibadem Ankara Hospital,
More informationJanuary 17, Re: Secretary s Advisory Committee on National Health Promotion and Disease Prevention Objectives for Healthy People 2030
January 17, 2019 Don Wright, MD, MPH, FAAFP Deputy Assistant Secretary for Health Office of Disease Prevention and Health Promotion Department of Health and Human Services Tower Building 1101 Wootton Parkway,
More informationOne Palliative Care Annual Report
One 203 Palliative Care Annual Report One In 202, ASCO released a provisional clinical opinion stating that concurrent palliative care should be considered early in the course of advanced or metastatic
More informationCommunity-acquired pneumonia (CAP)
Community-acquired pneumonia (CAP) Keith F Barker, MD GlaxoSmithKline 1 CAP: Key issues Definitions and patient population Use of prior antibiotics Microbiologically Evaluable population Efficacy endpoints
More informationAntimicrobial prophylaxis in liver transplant A multicenter survey endorsed by the European Liver and Intestine Transplant Association
Antimicrobial prophylaxis in liver transplant A multicenter survey endorsed by the European Liver and Intestine Transplant Association Els Vandecasteele, Jan De Waele, Dominique Vandijck, Stijn Blot, Dirk
More informationLong-Term Care Updates
Long-Term Care Updates April 2017 Bezlotoxumab to Prevent Recurrent Infection By Amy Wilson, PharmD and Zara Risoldi Cochrane, PharmD, MS, FASCP Introduction The Gram-positive bacteria is a common cause
More informationRenal Unit. Catheter Related Bacteraemia Guidelines
Renal Unit Policy Manager Drew Henderson Policy Group Renal Unit Policy Established 21/01/2014 Policy Review Period/Expiry 21/01/2015 Last Updated 21/01/2014 This policy does apply to Medical/Dental Staff
More informationThe Clinical Significance of Blood Cultures. Presented BY; Cindy Winfrey, MSN, RN, CIC, DON- LTC TM, VA- BC TM
The Clinical Significance of Blood Cultures Presented BY; Cindy Winfrey, MSN, RN, CIC, DON- LTC TM, VA- BC TM OVERVIEW Blood cultures are considered an important laboratory tool used to diagnose serious
More informationVenenkatheter-assoziierte Infektionen
Update Infektionen in der Hämatologie und Onkologie Venenkatheter-assoziierte Infektionen Georg Maschmeyer Potsdam www.dghoinfektionen.de Aktuelle Leitlinie der AGIHO...unter Berücksichtigung von: Ann
More informationPPD S EXPERT HEMATOLOGY AND ONCOLOGY TEAM
HEMATOLOGY ONCOLOGY PPD S EXPERT HEMATOLOGY AND ONCOLOGY TEAM COMMITTED TO ADVANCING DRUG DEVELOPMENT IN ONCOLOGY $ MARKETPLACE COMPLEXITIES increasingly competitive marketplace and rising cost pressures
More informationHABP/VABP Patient Outcomes from Previously Conducted Trials
HABP/VABP Patient Outcomes from Previously Conducted Trials Daniel Rubin, Ph.D. Food and Drug Administration Disclaimer: Slides represent views of the presenter and not necessarily of the FDA 1 Outline
More informationFacilitate physician access to compounded drugs for office-use from 503A compounding pharmacies for patients with emergent conditions;
By Electronic Delivery Scott Gottlieb, MD Commissioner Food and Drug Administration Attn: Division of Dockets Management (HFA-305) 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852 Re: FDA-2017-N-5093 for
More informationUnderstanding the Role of Palliative Care in the Treatment of Cancer Patients
Understanding the Role of Palliative Care in the Treatment of Cancer Patients Palliative care is derived from the Latin word palliare, to cloak. This is a form of medical care or treatment that concentrates
More informationClinical Impact of primary prophylaxis for FN in breast cancer patients. Prof. Young Jin Suh The Catholic University of Korea
Clinical Impact of primary prophylaxis for FN in breast cancer patients Prof. Young Jin Suh The Catholic University of Korea Objectives Describe the prevalence of febrile neutropenia in patients with breast
More informationInfluenza : What is going on? How can Community Health Centers help their patients?
Influenza 2008-2009: What is going on? How can Community Health Centers help their patients? Beth Nivin Bureau of Communicable Diseases New York City Dept. of Health and Mental Hygiene By the end of this
More informationESTABLISH 2 Top Line Data Release
The Future of Anti-Infectives ESTABLISH 2 Top Line Data Release March 25, 2013 1 Forward Looking Statements Statements contained in this data release regarding matters that are not historical facts are
More informationWorking Group Practices and Composition
November 26, 2018 Tickborne Disease Working Group Office of the Assistant Secretary for Health U.S. Department of Health and Human Services 200 Independence Avenue, SW Washington, DC 20201 Dear Tickborne
More informationTreatment of the afebrile patient after catheter withdrawal: drugs and duration J. A. Paiva and J. M. Pereira
REVIEW Treatment of the afebrile patient after catheter withdrawal: drugs and duration J. A. Paiva and J. M. Pereira Serviço de Cuidados Intensivos, Hospital de S. Joao, Porto, Portugal Catheter-related
More informationCare Guideline DRAFT for review cycle 08/02/17 CARE OF THE ADULT PNEUMONIA PATIENT
Care Guideline DRAFT for review cycle 08/02/17 CARE OF THE ADULT PNEUMONIA PATIENT Target Audience: All MHS employed providers within Primary Care, Urgent Care, and In-Hospital Care. The secondary audience
More informationThe Challenge of Managing Staphylococcus aureus Bacteremia
The Challenge of Managing Staphylococcus aureus Bacteremia M A R G A R E T G R A Y B S P F C S H P C L I N I C A L P R A C T I C E M A N A G E R N O R T H / I D P H A R M A C I S T A L B E R T A H E A
More informationHEALTHCARE-ASSOCIATED PNEUMONIA: EPIDEMIOLOGY, MICROBIOLOGY & PATHOPHYSIOLOGY
HEALTHCARE-ASSOCIATED PNEUMONIA: EPIDEMIOLOGY, MICROBIOLOGY & PATHOPHYSIOLOGY David Jay Weber, M.D., M.P.H. Professor of Medicine, Pediatrics, & Epidemiology Associate Chief Medical Officer, UNC Health
More informationSupplemental Online Case Discussion: Febrile Neutropenia
Supplemental Online Case Discussion: Febrile Neutropenia Alison C. Young, Fiona J. Collinson St James s Institute of Oncology, St James s University Hospital, Leeds, West Yorkshire, United Kingdom Case
More informationWork up of Respiratory & Wound Cultures:
Work up of Respiratory & Wound Cultures: Culture work up 2 Systematic approaches 1 Work up of Respiratory & Wound Cultures Resident flora Colonizing organisms Pathogens 2 Work up of Respiratory & Wound
More informationHospital-wide Impact of Mandatory Infectious Disease Consultation on Staphylococcus aureus Septicemia
Hospital-wide Impact of Mandatory Infectious Disease Consultation on Staphylococcus aureus Septicemia Amanda Guth 1 Amy Slenker MD 1,2 1 Department of Infectious Diseases, Lehigh Valley Health Network
More informationDAYTON CHILDREN S HOSPITAL CLINICAL PRACTICE GUIDELINES
DAYTON CHILDREN S HOSPITAL CLINICAL PRACTICE GUIDELINES DISCLAIMER: This Clinical Practice Guideline (CPG) generally describes a recommended course of treatment for patients with the identified health
More informationLemuel Shattuck Hospital Consultation Service
Lemuel Shattuck Hospital Consultation Service a) Goals, Objectives, and ACGME Competencies Goals Learn how to manage complicated infectious disease problems in a public health setting. Learn how to provide
More informationIssues regarding non-inferiority within the anti-bacterials area. Jon Armstrong, AstraZeneca Pharmaceuticals
Issues regarding non-inferiority within the anti-bacterials area Jon Armstrong, AstraZeneca Pharmaceuticals Topics Covered Disease area background The need for non-inferiority studies for anti-bacterials
More informationTowards a Sustainable Global Infrastructure for Medical Countermeasures
Towards a Sustainable Global Infrastructure for Medical Countermeasures Institute of Medicine The Public Health Emergency Medical Countermeasures Enterprise: Innovative Strategies to Enhance Products from
More informationRESPIRATORY VIRAL INFECTIONS IN PEDIATRIC ACUTE LEUKEMIA PATIENTS PRESENTING WITH FEBRILE NEUTROPENIA IN A TERTIARY HOSPITAL IN ANKARA, TURKEY
March 2019 Vol. 8 No. 1 Postgraduate Medical Journal of Ghana RESPIRATORY VIRAL INFECTIONS IN PEDIATRIC ACUTE LEUKEMIA PATIENTS PRESENTING WITH FEBRILE NEUTROPENIA IN A TERTIARY HOSPITAL IN ANKARA, TURKEY
More informationBIP Endotracheal Tube
Bactiguard Infection Protection BIP Endotracheal Tube For prevention of healthcare associated infections Ventilator associated pneumonia Infections of the respiratory tract are serious and common healthcare
More informationHealthcare-associated infections acquired in intensive care units
SURVEILLANCE REPORT Annual Epidemiological Report for 2015 Healthcare-associated infections acquired in intensive care units Key facts In 2015, 11 788 (8.3%) of patients staying in an intensive care unit
More informationDose-dependent effects of tobramycin in an animal model of Pseudomonas sinusitis Am J Rhino Jul-Aug; 21(4):423-7
AMINOGLYCOSIDES Dose-dependent effects of tobramycin in an animal model of Pseudomonas sinusitis Am J Rhino. 2007 Jul-Aug; 21(4):423-7 http://www.ncbi.nlm.nih.gov/pubmed/17882910 Evaluation of the in-vivo
More informationINTERNATIONAL SOCIETY FOR HEART AND LUNG TRANSPLANTATION a Society that includes Basic Science, the Failing Heart, and Advanced Lung Disease
International Society of Heart and Lung Transplantation Advisory Statement on the Implications of Pandemic Influenza for Thoracic Organ Transplantation This advisory statement has been produced by the
More informationFlu Watch. MMWR Week 3: January 14 to January 20, and Deaths. Virologic Surveillance. Influenza-Like Illness Surveillance
Flu Watch MMWR Week 3: January 14 to January 2, 218 All data are provisional and subject to change as more reports are received. Geographic Spread South Carolina reported widespread activity this week.
More informationInfluenza A (H1N1)pdm09 in Minnesota Epidemiology
Influenza A (H1N1)pdm09 in Minnesota Epidemiology Infectious Disease Epidemiology, Prevention and Control Division PO Box 64975 St. Paul, MN 55164-0975 Number of Influenza Hospitalizations by Influenza
More informationBelow is an overview of the oral and poster presentations featuring cefiderocol and S at IDWeek 2017:
SHIONOGI TO HIGHLIGHT RESEARCH ON CEFIDEROCOL (S-649266), A SIDEROPHORE CEPHALOSPORIN, AND S-033188, A CAP-DEPENDENT ENDONUCLEASE INHIBITOR FOR TREATMENT OF INFLUENZA, AT IDWEEK 2017 OSAKA, Japan and FLORHAM
More informationThe Hospital for Sick Children Technology Assessment at Sick Kids (TASK) EXECUTIVE SUMMARY
The Hospital for Sick Children Technology Assessment at Sick Kids (TASK) EXECUTIVE SUMMARY CASPOFUNGIN IN THE EMPIRIC TREATMENT OF FEBRILE NEUTROPENIA IN PEDIATRIC PATIENTS: A COMPARISON WITH CONVENTIONAL
More informationAcute respiratory illness This is a disease that typically affects the airways in the nose and throat (the upper respiratory tract).
Influenza glossary Adapted from the Centers for Disease Control and Prevention, US https://www.cdc.gov/flu/glossary/index.htm and the World Health Organization http://www.wpro.who.int/emerging_diseases/glossary_rev_sept28.pdf?ua=1
More informationFlu Watch. MMWR Week 4: January 21 to January 27, and Deaths. Virologic Surveillance. Influenza-Like Illness Surveillance
Flu Watch MMWR Week 4: January 21 to January 27, 218 All data are provisional and subject to change as more reports are received. Geographic Spread South Carolina reported widespread activity this week.
More informationGuidance for Industry Migraine: Developing Drugs for Acute Treatment
Guidance for Industry Migraine: Developing Drugs for Acute Treatment DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this draft
More informationEDUCATIONAL COMMENTARY CLOSTRIDIUM DIFFICILE UPDATE
EDUCATIONAL COMMENTARY CLOSTRIDIUM DIFFICILE UPDATE Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain FREE CME/CMLE credits click
More informationFoundations in Microbiology
Foundations in Microbiology Fifth Edition Talaro Chapter 13 Microbe Human Interactions: Infection and Disease Chapter 13 2 3 Infection a condition in which pathogenic microbes penetrate host defenses,
More informationTop 5 papers in clinical mycology
Top 5 papers in clinical mycology Dirk Vogelaers Department of General Internal Medicine University Hospital Ghent Joint symposium BVIKM/BSIMC and SBMHA/BVMDM Influenza-associated aspergillosis in critically
More informationPedsCases Podcast Scripts
PedsCases Podcast Scripts This is a text version of a podcast from Pedscases.com on Febrile Neutropenia. These podcasts are designed to give medical students an overview of key topics in pediatrics. The
More informationInfectious complications in children with acute myeloid leukemia: decreased mortality in multicenter trial AML-BFM 2004
OPEN Citation: (2016) 6, e382; doi:10.1038/bcj.2015.110 www.nature.com/bcj ORIGINAL ARTICLE Infectious complications in children with acute myeloid leukemia: decreased mortality in multicenter trial AML-BFM
More informationOral Dose of TAMIFLU for Treatment (twice daily for 5 days) of Influenza in Pediatric Patients One Year of Age and Older by
Table 1 () Oral Dose of for Treatment (twice daily for 5 days) of Influenza in Pediatric Patients One Year of Age and Older by (lbs) Dose for 5 Days Amount of for Oral Suspension to Withdraw for Each Dose
More informationNeutropenic Fever 1 InpatientPediatric Treatment
Neutropenic Fever 1 InpatientPediatric Treatment (Solid Tumors) Note: This algorithm should not be used for patients receiving CAR cell therapy. Page 1 of 7 Patient presents with fever or develops fever
More informationSkin and soft tissue (SSTI) sepsis (surgery, antimicrobial therapy and more)
Skin and soft tissue (SSTI) sepsis (surgery, antimicrobial therapy and more) Christian Eckmann Antibiotic Stewardship Expert ECDC Chief of Staff Department of General, Visceral and Thoracic Surgery Klinikum
More informationInfectious Diseases Pharmacy Content Outline June 2017
Infectious Diseases Pharmacy Content Outline June 2017 The following domains, tasks and knowledge statements were delineated by the BPS Infectious Disease Pharmacy Practice Analysis Taskforce and validated
More informationWARNING LETTER DEPARTMENT OF HEALTH & HUMAN SERVICES TRANSMITTED BY FACSIMILE
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Rockville, MD 20857 TRANSMITTED BY FACSIMILE Henry A. McKinnell, Jr., Ph.D. Chairman of the Board and Chief Executive
More informationPerformance of a modified MASCC index score for identifying low-risk febrile neutropenic cancer patients
DOI 10.1007/s00520-007-0347-3 ORIGINAL ARTICLE Performance of a modified MASCC index score for identifying low- febrile neutropenic cancer patients Luciano de Souza Viana & José Carlos Serufo & Manoel
More informationCARE OF THE ADULT PNEUMONIA PATIENT
Care Guideline CARE OF THE ADULT PNEUMONIA PATIENT Target Audience: The target audience for this Care Guideline is all MultiCare providers and staff, including those associated with our clinically integrated
More informationTestimony of the Association for Professionals in Infection Control and Epidemiology (APIC) and
Testimony of the Association for Professionals in Infection Control and Epidemiology (APIC) and The Society for Healthcare Epidemiology of America (SHEA) to the U.S. House of Representatives Appropriations
More informationManagement of Infections in Palliative Care Patients with Advanced Cancer
64 Journal of Pain and Symptom Management Vol. 24 No. 1 July 2002 Review Article Management of Infections in Palliative Care Patients with Advanced Cancer Stephanie Nagy-Agren, MD, and Harold B. Haley,
More informationCHEST VOLUME 117 / NUMBER 4 / APRIL, 2000 Supplement
CHEST VOLUME 117 / NUMBER 4 / APRIL, 2000 Supplement Evidence-Based Assessment of Diagnostic Tests for Ventilator- Associated Pneumonia* Executive Summary Ronald F. Grossman, MD, FCCP; and Alan Fein, MD,
More informationSevere β-lactam allergy. Alternative (use for mild-moderate β-lactam allergy) therapy
Recommended Empirical Antibiotic Regimens for MICU Patients Notes: The antibiotic regimens shown are general guidelines and should not replace clinical judgment. Always assess for antibiotic allergies.
More informationAilyn T. Isais-Agdeppa, MD*, Lulu Bravo, MD*
A FIVE-YEAR RETROSPECTIVE STUDY ON THE COMMON MICROBIAL ISOLATES AND SENSITIVITY PATTERN ON BLOOD CULTURE OF PEDIATRIC CANCER PATIENTS ADMITTED AT THE PHILIPPINE GENERAL HOSPITAL FOR FEBRILE NEUTROPENIA
More informationWhat s new in Infectious Diseases. Petronella Adomako, MD Infectious Disease Specialist Mckay-Dee Hospital
What s new in Infectious Diseases Petronella Adomako, MD Infectious Disease Specialist Mckay-Dee Hospital None Disclosures Objectives New information in infectious diseases. New diseases and outbreaks.
More informationOragenics Shareholder Update
January 4, 2017 Oragenics Shareholder Update Advances Drug Development Programs Focused on Conditions with Significant Unmet Medical Needs TAMPA, Fla.--(BUSINESS WIRE)-- Oragenics, Inc. (NYSE MKT:OGEN.BC),
More informationTwo-stage study designed to evaluate tolerability and efficacy of pracinostat combined with azacitidine in patients with high and very high risk MDS
Helsinn Group and MEI Pharma Announce First Patient Dosed in Phase 2 Dose-Optimization Study of Pracinostat and Azacitidine in Myelodysplastic Syndrome Two-stage study designed to evaluate tolerability
More informationGranix. Granix (tbo-filgrastim) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.85.16 Subject: Granix 1 of 7 Last Review Date: December 2, 2016 Granix Description Granix (tbo-filgrastim)
More informationQuality & Safety Committee Date: 22 June 2016 Agenda item: 4.4
SUMMARY REPORT ABM University Health Board Quality & Safety Committee Date: 22 June 20 Agenda item: 4.4 Subject Prepared by Approved by Infection Prevention & Control Delyth Davies, Head of Nursing, Infection
More informationThe Hospital for Sick Children Technology Assessment at SickKids (TASK) ABSTRACT
The Hospital for Sick Children Technology Assessment at SickKids (TASK) ABSTRACT CASPOFUNGIN IN THE EMPIRIC TREATMENT OF FEBRILE NEUTROPENIA IN PEDIATRIC PATIENTS: A COMPARISON WITH CONVENTIONAL AND LIPOSOMAL
More informationGUIDE TO INFECTION CONTROL IN THE HOSPITAL. Carbapenem-resistant Enterobacteriaceae
GUIDE TO INFECTION CONTROL IN THE HOSPITAL CHAPTER 47: Carbapenem-resistant Enterobacteriaceae Authors E-B Kruse, MD H. Wisplinghoff, MD Chapter Editor Michelle Doll, MD, MPH) Topic Outline Key Issue Known
More informationCytoDyn Announces Initiation of Metastatic Triple Negative Breast Cancer Trial and Reiterates Phase 3 Goal in Cancer
November 26, 2018 CytoDyn Announces Initiation of Metastatic Triple Negative Breast Cancer Trial and Reiterates Phase 3 Goal in Cancer VANCOUVER, Washington, Nov. 26, 2018 (GLOBE NEWSWIRE) -- CytoDyn Inc.
More informationGranix. Granix (tbo-filgrastim) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.10.16 Section: Prescription Drugs Effective Date: April 1, 2014 Subject: Granix 1 of 7 Last Review Date:
More informationGuideline on the evaluation of medicinal products indicated for treatment of bacterial infections (CPMP/EWP/558/95 rev 2)
Reflections on the methodological issues associated with the CHMP guideline on the evaluation of medicinal products indicated for treatment of bacterial infections Dr David Wright Contents Guideline on
More informationHow to prevent Infections in Patients undergoing allo-hsct?
How to prevent Infections in Patients undergoing allo-hsct? Olaf Penack EBMT Course, 29 Sept 1 Oct 2014, Naples, Italy #EBMT2014 www.ebmt.org Prevention of Infections Epidemiology and risk factors for
More informationEMA/FDA/Health Canada Workshop on Paediatric PAH
EMA/FDA/Health Canada Workshop on Paediatric PAH Industry Perspective Date: 12/06/2017 * Version: FINAL Industry perspective on partnering with academia and agencies in drug development for children with
More informationClinical Practice Guidelines: Clinical Practice Guidelines Can t Live With Them; Can t Live Without Them
Clinical Practice Guidelines: Can t Live With Them Can t Live Without Them Larry M. Lopez, Pharm.D., F.C.C.P. Professor Emeritus of Pharmacy & Medicine University of Florida College of Pharmacy Clinical
More informationInfectious Disease in the Critically Ill Patient
Infectious Disease in the Critically Ill Patient Heather L. Evans, MD MS FACS Director of Surgical Infectious Disease Harborview Medical Center Asst. Professor UW Department of Surgery New Antibiotics:
More informationSEPSIS RESULTING FROM PNEUMONIA FILE
13 January, 2018 SEPSIS RESULTING FROM PNEUMONIA FILE Document Filetype: PDF 521.12 KB 0 SEPSIS RESULTING FROM PNEUMONIA FILE Aspiration pneumonia is a type of lung infection. CAP's symptoms are the result
More informationRARE DISEASE. THE POWER OFx. Experts. Experienc e. Execution. Challenges Conducting Rare Disease Studies. Experts: Experience: Execution:
THE POWER OFx TM Experts. Experienc e. Execution. The Power of X in Rare Disease Experts: Committed cross-functional team of Rare Disease experts comprised of doctors, project managers, regulatory consultants,
More informationOutpatient parenteral antibiotic therapy with daptomycin: insights from a patient registry
doi: 10.1111/j.1742-1241.2008.01824.x ORIGINAL PAPER Outpatient parenteral antibiotic therapy with daptomycin: insights from a patient registry W. J. Martone, K. C. Lindfield, D. E. Katz OnlineOpen: This
More informationNational Institute for Health and Care Excellence. Single Technology Appraisal (STA)
Single Technology Appraisal (STA) Tisagenlecleucel-T for previously treated B-cell acute lymphoblastic Response to consultee and commentator comments on the draft remit and draft scope (pre-referral) Please
More informationGranix. Granix (tbo-filgrastim) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.10.16 Subject: Granix 1 of 7 Last Review Date: September 18, 2015 Granix Description Granix (tbo-filgrastim)
More informationAntimicrobial Stewardship in Community Acquired Pneumonia
Antimicrobial Stewardship in Community Acquired Pneumonia Medicine Review Course 2018 Dr Lee Tau Hong Consultant Department of Infectious Diseases National Centre for Infectious Diseases Scope 1. Diagnosis
More informationMerck Pipeline. As of August 3, 2015
Merck Pipeline As of August 3, 2015 Merck Pipeline as of August 3, 2015 Phase 2 Phase 2 Phase 3 Phase 3 Phase 3 Alzheimer s Disease MK-7622 Contraception, Next Generation Ring MK-8342B Allergy, House Dust
More informationEmerging Respiratory Infections NZ Amanda McNaughton Respiratory Physician CCDHB Wellington
Emerging Respiratory Infections NZ 2015 Amanda McNaughton Respiratory Physician CCDHB Wellington Respiratory Infection: overview Influenza virus Clinical picture Emerging infection New Zealand Influenza
More informationClinical Trial Data Supporting FDA Clearance of the T2Bacteria Panel Versus Blood Culture for the Diagnosis of Bacteremia
Clinical Trial Data Supporting FDA Clearance of the T2Bacteria Panel Versus Blood Culture for the Diagnosis of Bacteremia New diagnostic test overcomes time, sensitivity, and antimicrobial interference
More informationGuideline for the Management of Fever and Neutropenia in Children with Cancer and/or Undergoing Hematopoietic Stem-Cell Transplantation
Guideline for the Management of Fever Neutropenia in Children with Cancer /or Undergoing Hematopoietic Stem-Cell Transplantation COG Supportive Care Endorsed Guidelines Click here to see all the COG Supportive
More informationSubmitted electronically to:
Submitted electronically to: ODOARRFI19@nih.gov Maureen Goodenow, PhD Associate Director of AIDS Research, NIH Director, Office of AIDS Research (OAR) National Institutes of Health 5601 Fishers Lane. Room
More informationCATHETER-ASSOCIATED URINARY TRACT INFECTIONS
CATHETER-ASSOCIATED URINARY TRACT INFECTIONS Hamid Emadi M.D Associate professor of Infectious diseases Department Tehran university of medical science The most common nosocomial infection The urinary
More informationInspections, Compliance, Enforcement, and Criminal Investigations
Home Inspections, Compliance, Enforcement, and Criminal Investigations Enforcement Actions Warning Letters Inspections, Compliance, Enforcement, and Criminal Investigations Burzynski Research Institute
More information(908) (908)
Contact: Robert J. Hugin Brian P. Gill Senior VP and CFO Director, PR/IR Celgene Corporation Celgene Corporation (908) 673-9102 (908) 673-9530 REVLIMID (lenalidomide) SIGNIFICANTLY DELAYS TIME TO DISEASE
More information